Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell
Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February.
You may also be interested in...
The company hopes to sidestep payer restrictions and patient abandonment by launching the cholesterol-lowering medicine at a palatable price point in line with where branded statins were before patent expiry.
Final Phase III study for pivotal package of cholesterol drug bempedoic acid shows LDL-lowering efficacy and a clean safety profile, paving the way for filings in the first half of 2019.
Biotech gets $190m up front in partnership that will discover small molecule RNA-targeted therapies against a range of targets selected by Roche. Arrakis thinks its technology can drug difficult-to-reach targets.